Press Coverage

FDA Clearance for Cellvizio + Pafolacianine for Molecular Imaging

9 May 2022

The US FDA has granted 510(k) clearance (K220477) for the use of the Cellvizio 100 Series platform with a molecular imaging agent called Pafolacianine (Cytalux) for real-time in vivo visualization during endoscopic, laparoscopic, and needle-based procedures, according to Mauna Kea Technologies.

Latest News

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

No results found.